| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | 뇌졸중의 치료 또는 예방 방법 | KR1020177016154 | 2015-11-17 | KR1020170082631A | 2017-07-14 | 에릭손울프; 닐슨잉그리스; 로렌스다니엘; 조수엔밍 |
| 개체의뇌졸중의영향을감소시키는방법으로서, 상기방법은개체에 VEGF-B 신호전달을억제하는화합물을투여하는것을포함한다. | ||||||
| 62 | ＰＡＩ―１ 작용의 치료학적 억제제 및 이의 사용 방법 | KR1020107017701 | 2009-01-09 | KR101712208B1 | 2017-03-03 | 리드,토마스,디.; 피터슨,리차드,이.; 리드,찰스,씨.; 마짜렐리소피친스키,조안; 메러닉,베타니,엘.; 칼슨,조나단; 배어,캐써린,엘.; 타세바,엘레나 |
| 본발명은포유류 PAI-Ⅰ리간드및 조절자에관한것이다. 특히, 본발명은 PAI-1의리간드및/또는조절인자인폴리펩타이드, 폴리펩타이드조성물및 폴리펩타이드를암호화하는폴리뉴클레오타이드에관한것이다. 본발명은 PAI-Ⅰ활성을조절하는호모폴리리간드 (homopolyligand) 또는헤테로폴리리간드 (heteropolyligand)인폴리리간드에관한것이다. 본발명은또한세포의영역에국재화된리간드및 폴리리간드에관한것이다. 본발명은또한 PAI-Ⅰ리간드및 폴리리간드의공간적조절을제공하기위해사용될수 있는국재화테터(tether) 및프로모터서열에관한것이다. 본발명은또한 PAI-Ⅰ리간드및 폴리리간드의일시적인조절을제공하는데사용될수 있는유도성유전자스위치(gene switch)에관한것이다. 본발명은또한죽상경화증을치료또는예방하는방법에관한것이다. 본발명은또한섬유증을치료하거나예방하는방법에관한것이다. | ||||||
| 63 | 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제 | KR1020177002633 | 2007-07-05 | KR1020170014023A | 2017-02-07 | 매디슨에드윈엘. |
| 본원은기질특이성또는기타성질이변형된프로테아제를확인하는방법을제공한다. 상기방법은, 기질의절단시안정한복합체를형성함에의해프로테아제를포획하는서핀, 알파마크로글로불린또는 p35 계열단백질또는변형된서핀및 변형된 p35 계열구성원또는변형된알파마크로글로불린과같은기질을프로테아제와접촉시켜후보물및 변형된프로테아제를스크리닝하는것이다. 또한본원은변형된프로테아제를제공한다. | ||||||
| 64 | 생물학적 활성 화물의 경구 전달용 콜릭스 독소-유래 융합 분자 | KR1020167034104 | 2015-05-07 | KR1020170013893A | 2017-02-07 | 미시즈니,랜돌,제이.; 마무드,타히르 |
| 본발명은염증성질환, 자가면역질환, 암, 대사성장애, 및성장결핍장애의치료를위해, 개선되고효과적인치료법을제공하도록설계되고, 피험자에게경구전달을위해제형화된, 비-자연적으로발생하는융합분자및 하나이상의약학적으로허용가능한담체를포함하는약학조성물에관한것이다. | ||||||
| 65 | 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제 | KR1020157003739 | 2007-07-05 | KR1020150033726A | 2015-04-01 | 매디슨에드윈엘. |
| 본원은기질특이성또는기타성질이변형된프로테아제를확인하는방법을제공한다. 상기방법은, 기질의절단시안정한복합체를형성함에의해프로테아제를포획하는서핀, 알파마크로글로불린또는 p35 계열단백질또는변형된서핀및 변형된 p35 계열구성원또는변형된알파마크로글로불린과같은기질을프로테아제와접촉시켜후보물및 변형된프로테아제를스크리닝하는것이다. 또한본원은변형된프로테아제를제공한다. | ||||||
| 66 | 미락 단백질 | KR1020117022908 | 2010-03-09 | KR1020110136825A | 2011-12-21 | 쇼트,제이,엠.; 창,화이,웬; 프레이,거하드; 프로스트,그레고리 |
| 본 발명은, 야생형 정상 생리학적 조건에서 가역적으로 또는 비가역적으로 비활성화되는 야생형 단백질, 특히 치료용 단백질로부터 조건 활성 생체 단백질을 생성하는 방법에 관한 것이다. 예를 들어, 진화된 단백질은 사실상 체온에서는 비활성이지만, 더 낮은 온도에서는 활성이다. | ||||||
| 67 | ＰＡＩ―１ 작용의 치료학적 억제제 및 이의 사용 방법 | KR1020107017701 | 2009-01-09 | KR1020100129271A | 2010-12-08 | 리드,토마스,디.; 피터슨,리차드,이.; 리드,찰스,씨.; 마짜렐리소피친스키,조안; 메러닉,베타니,엘.; 칼슨,조나단; 배어,캐써린,엘.; 타세바,엘레나 |
| 본 발명은 포유류 PAI-Ⅰ 리간드 및 조절자에 관한 것이다. 특히, 본 발명은 PAI-1의 리간드 및/또는 조절인자인 폴리펩타이드, 폴리펩타이드 조성물 및 폴리펩타이드를 암호화하는 폴리뉴클레오타이드에 관한 것이다. 본 발명은 PAI-Ⅰ 활성을 조절하는 호모폴리리간드 (homopolyligand) 또는 헤테로폴리리간드 (heteropolyligand)인 폴리리간드에 관한 것이다. 본 발명은 또한 세포의 영역에 국재화된 리간드 및 폴리리간드에 관한 것이다. 본 발명은 또한 PAI-Ⅰ 리간드 및 폴리리간드의 공간적 조절을 제공하기 위해 사용될 수 있는 국재화 테터(tether) 및 프로모터 서열에 관한 것이다. 본 발명은 또한 PAI-Ⅰ 리간드 및 폴리리간드의 일시적인 조절을 제공하는데 사용될 수 있는 유도성 유전자 스위치(gene switch)에 관한 것이다. 본 발명은 또한 죽상경화증을 치료 또는 예방하는 방법에 관한 것이다. 본 발명은 또한 섬유증을 치료하거나 예방하는 방법에 관한 것이다.
|
||||||
| 68 | 플라스미드, 이의 작제방법 및 플라스미노겐 활성자 제조에 있어서의 이의 용도 | KR1019900010860 | 1990-07-18 | KR100167761B1 | 1999-01-15 | 레기나에,브리겔우스-플로어; 레오폴트플로어; 볼프강힐렌; 게르트요오트,스테펜스; 볼프강스트라스부르거; 마르틴알.에프.빌헬름 |
| 내용 없음. | ||||||
| 69 | 우로키나제 전구체를 안정화시키는 방법 | KR1019860002879 | 1986-04-15 | KR1019940003056B1 | 1994-04-13 | 나리따슈사꾸; 콘도마사히데; 이시가와쇼이찌; 오오하라가즈히로; 모리모또가즈오 |
| 내용 없음. | ||||||
| 70 | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | US15616140 | 2017-06-07 | US10130688B2 | 2018-11-20 | Randall Mrsny; Tahir Mahmood |
| The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes. | ||||||
| 71 | METHOD OF TREATING OR PREVENTING STROKE | US15527066 | 2015-11-17 | US20180237513A1 | 2018-08-23 | Ulf ERIKSSON; Ingrid NILSSON; Daniel LAWRENCE; Enming Joe SU |
| A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling | ||||||
| 72 | DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA | US15859075 | 2017-12-29 | US20180185475A1 | 2018-07-05 | Lawrence M. KAUVAR; Damir JANIGRO |
| Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity. | ||||||
| 73 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF AN ENZYME TO A SUBJECT'S AIRWAY | US15571529 | 2016-05-06 | US20180140547A1 | 2018-05-24 | Robert O. WILLIAMS, III; Steven IDELL |
| Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI). | ||||||
| 74 | Materials and methods for delivering compositions to selected tissues | US15004790 | 2016-01-22 | US09937129B2 | 2018-04-10 | William R. Freeman; Michael J. Sailor; Lingyun Cheng |
| This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics. | ||||||
| 75 | STABLE INJECTABLE COMPOSITION OF PHARMACEUTICALLY ACTIVE AGENTS AND PROCESS FOR ITS PREPARATION | US15519435 | 2015-10-15 | US20170239335A1 | 2017-08-24 | Vandana SONAVARIA; Kamal Kumar UPADHYAY |
| The present invention relates to a stable, non-aqueous and ready-to-use injectable composition of a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. The present invention also relates to a process for the preparation of the stable, non-aqueous and ready-to-use injectable composition of pharmaceutically active agent involving use of a non-solvent solvent system suitable for preparing a stabilized injectable composition comprising a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. It is not required to reconstitute the injectable composition of pharmaceutically active agent with water prior to administration, thereby rendering it an easy-to-use injectable composition. | ||||||
| 76 | Mirac proteins | US14464059 | 2014-08-20 | US09637735B2 | 2017-05-02 | Jay M. Short; Hwai Wen Chang; Gerhard Frey |
| This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | ||||||
| 77 | MIRAC PROTEINS | US15337283 | 2016-10-28 | US20170044522A1 | 2017-02-16 | Jay M. Short; Hwai Wen Chang; Gerhard Frey |
| This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | ||||||
| 78 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | US14817690 | 2015-08-04 | US09527878B2 | 2016-12-27 | Daniel A. Lawrence; Cory Emal; Jacqueline Cale; Enming Joe Su; Mark Warnock; Shih-Hon Li; Jeanne Ann Cupp |
| The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels. | ||||||
| 79 | POLYMERS FOR DELIVERY OF THERAPEUTIC PROTEINS | US14870807 | 2015-09-30 | US20160106846A1 | 2016-04-21 | Michael KOETTING; Nicholas PEPPAS |
| In some aspects, improved hydrogel copolymers (e.g., comprising itaconic acid and N-vinylpyrrolidone) are provided and may be used, e.g., for oral delivery of a therapeutic protein. In some embodiments, improved methods for loading a therapeutic protein (e.g., a high isoelectric point protein) into a hydrogel copolymer are provided, and may comprise incubating the therapeutic protein and the hydrogel in a reduced ionic strength loading solution. In some embodiments, use of the reduced ionic strength loading solution can result in hydrogel copolymer-therapeutic protein compositions that display improved pharmacokinetic attributes, e.g., improved loading and/or release of a therapeutic protein. | ||||||
| 80 | Materials and methods for delivering compositions to selected tissues | US13887045 | 2013-05-03 | US09241906B2 | 2016-01-26 | William R. Freeman; Michael J. Sailor; Lingyun Cheng |
| This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics. | ||||||
QQ群二维码
意见反馈
意见反馈